Margaret Beaudoin - Jun 16, 2021 Form 3 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Vice President, Finance
Signature
/s/ Andrew Ashe, Attorney-in-Fact
Stock symbol
VERV
Transactions as of
Jun 16, 2021
Transactions value $
$0
Form type
3
Date filed
6/16/2021, 07:29 PM
Next filing
Jun 21, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 10.8K $8.24 Direct F1
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 54K $2.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 12, 2021 for 10,799 shares. 25% the shares underlying the option will vest on February 1, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until February 1, 2025.
F2 The option was granted on September 16, 2020 for 53,998 shares. 25% the shares underlying the option will vest on June 8, 2021, and the remainder are scheduled to vest in equal monthly installments thereafter until June 8, 2024.

Remarks:

Exhibit Index: 24.1 Power of Attorney